Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 1/2013

01-01-2013 | Research Paper

Characterization of the inflammatory response to solid cancer metastases in the human brain

Authors: Anna Sophie Berghoff, Hans Lassmann, Matthias Preusser, Romana Höftberger

Published in: Clinical & Experimental Metastasis | Issue 1/2013

Login to get access

Abstract

New immunomodulatory agents showed promising activity in brain metastases (BM). However, little is known about the inflammatory response in BM. New insights are needed to further guide the development of treatment strategies. We investigated 17 human autoptic tissue specimens of BM from breast cancer (n = 3), non-small cell lung cancer (NSCLC; n = 5), small cell lung cancer (n = 3) and melanoma (n = 6). Immunohistochemical staining for a comprehensive panel of 21 inflammation-associated markers was performed. Results were quantified by manual counting of the various cell populations in three areas of 0.5 mm2 (intratumoral, peritumoral, control region). Profound microglia activation with marked peritumoral accumulation and some intratumoral infiltration of HLA-DR-positive microglia/macrophages was found. A high proportion of these cells showed strong immunoreactivity for phagocytosis associated markers and MHC class 1, while a smaller subgroup of cells expressed molecules involved in radical production. Only few B- and T-lymphocytes were observed in and around BM. The number of CD8-positive T-cells was not correlated to MHC class 1 expression on tumor cells and only a fraction of T-cells showed Granzym B expression. Melanoma BM had significantly less accumulation of peritumoral microglia than NSCLC BM. The inflammatory pattern was independent from treatment of patients with glucocorticoids or radiation. The inflammatory reaction to BM is mainly characterized by activation of microglia/macrophages and shows pronounced upregulation of markers involved in phagocytosis, but seem to be insufficient in activating adaptive immunity. Treatment strategies aimed at activating specific immunity may potentiate immune attack on tumor cells.
Literature
1.
2.
Tsao M, Xu W, Sahgal A (2012) A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases. Cancer 118(9):2486–2493
3.
Kienast Y, Winkler F (2010) Therapy and prophylaxis of brain metastases. Expert Rev Anticancer Ther 10(11):1763–1777PubMedCrossRef
4.
Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, McKenna WG, Byhardt R (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37(4):745–751PubMedCrossRef
5.
Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, Bhatt A, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M (2012) Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 30(4):419–425PubMedCrossRef
6.
Mehta MP, Paleologos NA, Mikkelsen T, Robinson PD, Ammirati M, Andrews DW, Asher AL, Burri SH, Cobbs CS, Gaspar LE, Kondziolka D, Linskey ME, Loeffler JS, McDermott M, Olson JJ, Patchell RA, Ryken TC, Kalkanis SN (2010) The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 96(1):71–83PubMedCrossRef
7.
Soffietti R, Cornu P, Delattre JY, Grant R, Graus F, Grisold W, Heimans J, Hildebrand J, Hoskin P, Kalljo M, Krauseneck P, Marosi C, Siegal T, Vecht C (2006) EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force. Eur J Neurol 13(7):674–681PubMedCrossRef
8.
Preusser M, Capper D, Ilhan-Mutlu A, Berghoff AS, Birner P, Bartsch R, Marosi C, Zielinski C, Mehta MP, Winkler F, Wick W, von Deimling A (2012) Brain metastases: pathobiology and emerging targeted therapies. Acta Neuropathol 123(2):205–222PubMedCrossRef
9.
Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13(5):459–465
10.
Sriram S (2011) Role of glial cells in innate immunity and their role in CNS demyelination. J Neuroimmunol 239(1–2):13–20PubMedCrossRef
11.
12.
13.
Amor S, Puentes F, Baker D, van der Valk P (2010) Inflammation in neurodegenerative diseases. Immunology 129(2):154–169PubMedCrossRef
14.
He BP, Wang JJ, Zhang X, Wu Y, Wang M, Bay BH, Chang AY (2006) Differential reactions of microglia to brain metastasis of lung cancer. Mol Med 12(7–8):161–170PubMed
15.
Zhang M, Olsson Y (1995) Reactions of astrocytes and microglial cells around hematogenous metastases of the human brain. Expression of endothelin-like immunoreactivity in reactive astrocytes and activation of microglial cells. J Neurol Sci 134(1–2):26–32PubMedCrossRef
16.
Mittelbronn M, Platten M, Zeiner P, Dombrowski Y, Frank B, Zachskorn C, Harter PN, Weller M, Wischhusen J (2011) Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression. Acta Neuropathol 122(3):353–365PubMedCrossRef
17.
Mittelbronn M, Simon P, Loffler C, Capper D, Bunz B, Harter P, Schlaszus H, Schleich A, Tabatabai G, Goeppert B, Meyermann R, Weller M, Wischhusen J (2007) Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. J Neuroimmunol 189(1–2):50–58PubMedCrossRef
18.
19.
20.
Neves S, Mazal PR, Wanschitz J, Rudnay AC, Drlicek M, Czech T, Wustinger C, Budka H (2001) Pseudogliomatous growth pattern of anaplastic small cell carcinomas metastatic to the brain. Clin Neuropathol 20(1):38–42PubMed
21.
De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J, Sciot R, Wilms G, Demaerel P, Warmuth-Metz M, Soerensen N, Wolff JE, Wagner S, Kaempgen E, Van Gool SW (2008) Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 14(10):3098–3104PubMedCrossRef
22.
Weber JS, Amin A, Minor D, Siegel J, Berman D, O’Day SJ (2011) Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 21(6):530–534PubMedCrossRef
23.
Finocchiaro G, Pellegatta S (2011) Immunotherapy for glioma: getting closer to the clinical arena? Curr Opin Neurol 24(6):641–647PubMedCrossRef
24.
Dringen R (2005) Oxidative and antioxidative potential of brain microglial cells. Antioxid Redox Signal 7(9–10):1223–1233PubMedCrossRef
25.
Daginakatte GC, Gutmann DH (2007) Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet 16(9):1098–1112PubMedCrossRef
26.
Brantley EC, Guo L, Zhang C, Lin Q, Yokoi K, Langley RR, Kruzel E, Maya M, Kim SW, Kim SJ, Fan D, Fidler IJ (2010) Nitric oxide-mediated tumoricidal activity of murine microglial cells. Transl Oncol 3(6):380–388PubMed
27.
Dal Bianco A, Bradl M, Frischer J, Kutzelnigg A, Jellinger K, Lassmann H (2008) Multiple sclerosis and Alzheimer’s disease. Ann Neurol 63(2):174–183PubMedCrossRef
28.
Haider L, Fischer MT, Frischer JM, Bauer J, Hoftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H (2011) Oxidative damage in multiple sclerosis lesions. Brain 134(Pt 7):1914–1924PubMedCrossRef
29.
Kamata T (2009) Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci 100(8):1382–1388PubMedCrossRef
30.
Murata J, Corradin SB, Janzer RC, Juillerat-Jeanneret L (1994) Tumor cells suppress cytokine-induced nitric-oxide (NO) production in cerebral endothelial cells. Int J Cancer 59(5):699–705PubMedCrossRef
31.
Noda M, Seike T, Fujita K, Yamakawa Y, Kido M, Iguchi H (2009) The role of immune cells in brain metastasis of lung cancer cells and neuron-tumor cell interaction. Ross Fiziol Zh Im I M Sechenova 95(12):1386–1396PubMed
32.
Strik HM, Stoll M, Meyermann R (2004) Immune cell infiltration of intrinsic and metastatic intracranial tumours. Anticancer Res 24(1):37–42PubMed
33.
Huang Y, Yin H, Han J, Huang B, Xu J, Zheng F, Tan Z, Fang M, Rui L, Chen D, Wang S, Zheng X, Wang CY, Gong F (2007) Extracellular hmgb1 functions as an innate immune-mediator implicated in murine cardiac allograft acute rejection. Am J Transplant 7(4):799–808PubMedCrossRef
34.
Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960–1964PubMedCrossRef
35.
de Jong RA, Leffers N, Boezen HM, ten Hoor KA, van der Zee AG, Hollema H, Nijman HW (2009) Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol 114(1):105–110PubMedCrossRef
36.
Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW (2009) Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 58(3):449–459PubMedCrossRef
37.
Robert C, Thomas L, Bondarenko I, O’Day S, M DJ, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH, Jr., Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364(26): 2517–2526
38.
Loeffler C, Dietz K, Schleich A, Schlaszus H, Stoll M, Meyermann R, Mittelbronn M (2011) Immune surveillance of the normal human CNS takes place in dependence of the locoregional blood-brain barrier configuration and is mainly performed by CD3(+)/CD8(+) lymphocytes. Neuropathology 31(3):230–238PubMedCrossRef
39.
Bradl M, Hohlfeld R (2003) Molecular pathogenesis of neuroinflammation. J Neurol Neurosurg Psychiatry 74(10):1364–1370PubMedCrossRef
40.
Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM (2011) Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 17(6):1603–1615PubMedCrossRef
41.
Roth P, Mittelbronn M, Wick W, Meyermann R, Tatagiba M, Weller M (2007) Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. Cancer Res 67(8):3540–3544PubMedCrossRef
42.
Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, Wiendl H (2007) WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? Acta Neuropathol 114(2):111–119PubMedCrossRef
43.
Schneider T, Becker A, Ringe K, Reinhold A, Firsching R, Sabel BA (2008) Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles. J Neuroimmunol 195(1–2):21–27PubMedCrossRef
44.
45.
46.
Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL (1990) HLA-A- and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 2(2):113–125PubMedCrossRef
47.
Mattiace LA, Davies P, Dickson DW (1990) Detection of HLA-DR on microglia in the human brain is a function of both clinical and technical factors. Am J Pathol 136(5):1101–1114PubMed
48.
Martinez-Pomares L, Platt N, McKnight AJ, da Silva RP, Gordon S (1996) Macrophage membrane molecules: markers of tissue differentiation and heterogeneity. Immunobiology 195(4–5):407–416PubMedCrossRef
49.
Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, Kohsaka S (1998) Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 57(1):1–9PubMedCrossRef
50.
Ahmed Z, Shaw G, Sharma VP, Yang C, McGowan E, Dickson DW (2007) Actin-binding proteins coronin-1a and IBA-1 are effective microglial markers for immunohistochemistry. J Histochem Cytochem 55(7):687–700PubMedCrossRef
51.
Avril T, Attrill H, Zhang J, Raper A, Crocker PR (2006) Negative regulation of leucocyte functions by CD33-related siglecs. Biochem Soc Trans 34(Pt 6):1024–1027PubMed
52.
Bien CG, Bauer J, Deckwerth TL, Wiendl H, Deckert M, Wiestler OD, Schramm J, Elger CE, Lassmann H (2002) Destruction of neurons by cytotoxic T-cells: a new pathogenic mechanism in Rasmussen’s encephalitis. Ann Neurol 51(3):311–318PubMedCrossRef
53.
Payne J, Maher F, Simpson I, Mattice L, Davies P (1997) Glucose transporter Glut 5 expression in microglial cells. Glia 21(3):327–331PubMedCrossRef
54.
Smith KJ, Lassmann H (2002) The role of nitric oxide in multiple sclerosis. Lancet Neurol 1(4):232–241PubMedCrossRef
55.
Bruce-Keller AJ, Gupta S, Parrino TE, Knight AG, Ebenezer PJ, Weidner AM, LeVine H 3rd, Keller JN, Markesbery WR (2010) NOX activity is increased in mild cognitive impairment. Antioxid Redox Signal 12(12):1371–1382PubMedCrossRef
56.
Janeway CA (2002) Immunology, 5 edn. Garland Publishing, Heidelberg
57.
Rousalova I, Krepela E (2010) Granzyme B-induced apoptosis in cancer cells and its regulation (review). Int J Oncol 37(6):1361–1378PubMed
Metadata
Title
Characterization of the inflammatory response to solid cancer metastases in the human brain
Authors
Anna Sophie Berghoff
Hans Lassmann
Matthias Preusser
Romana Höftberger
Publication date
01-01-2013
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 1/2013
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-012-9510-4

Other articles of this Issue 1/2013

Clinical & Experimental Metastasis 1/2013 Go to the issue

Research Paper

Development of a tridimensional microvascularized human skin substitute to study melanoma biology

Research Paper

Expression of TGFβ3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement of PI3-kinase/AKT signaling pathway

Research Paper

Anti-LFA-1 antibodies enhance metastasis of ocular lymphoma to the brain and contralateral eye

Research Paper

Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy

Reseach Paper

Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer

Research Paper

Dipyridamole prevents triple-negative breast-cancer progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits